TABLE 1.
Sinus surgery history of patients with CRSwNP from SINUS‐24+SINUS‐52*
| Patients |
Placebo (n = 286) |
Dupilumab 300 mg q2w (n = 438) |
All patients (n = 724) |
|---|---|---|---|
| No prior surgeries, n (%) | 99 (34.6) | 166 (37.9) | 265 (36.6) |
| Number of prior surgeries, n (%) | |||
| ≥1 prior surgery | 187 (65.4) | 272 (62.1) | 459 (63.4) |
| 1 | 101 (54.0) | 153 (56.3) | 254 (55.3) |
| 2 | 39 (20.9) | 55 (20.2) | 94 (20.5) |
| ≥3 | 47 (25.1) | 64 (23.5) | 111 (24.2) |
| Number of prior surgeries, mean ± SD | 1.96 ± 1.45 | 1.96 ± 1.64 | 1.96 ± 1.56 |
| Time since last surgery, n (%)a | |||
| <3 years | 55 (29.4) | 81 (29.8) | 136 (29.6) |
| ≥3 and <5 years | 34 (18.2) | 47 (17.3) | 81 (17.6) |
| ≥5 and <10 years | 53 (28.3) | 80 (29.4) | 133 (29.0) |
| ≥10 years | 45 (24.1) | 63 (23.2) | 108 (23.5) |
| Time since last surgery (years), median (Q1:Q3) | 5.24 (2.62:9.83) | 5.33 (2.53:9.62) | 5.31 (2.56:9.62) |
*Percentages for patients with 1, 2, or ≥3 prior surgeries and for time since last surgery subgroups were calculated using the number of patients with ≥1 surgery as the denominator.
a
Data for time since last surgery were missing for 1 patient.
CRSwNP = chronic rhinosinusitis with nasal polyps; Q1 = first quartile; Q3 = third quartile; q2w = every 2 weeks; SD = standard deviation.